Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
Main Authors: | Andrew R Conery, Richard C Centore, Adrianne Neiss, Patricia J Keller, Shivangi Joshi, Kerry L Spillane, Peter Sandy, Charlie Hatton, Eneida Pardo, Laura Zawadzke, Archana Bommi-Reddy, Karen E Gascoigne, Barbara M Bryant, Jennifer A Mertz, Robert J Sims III |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2016-07-01
|
Series: | eLife |
Online Access: | https://elifesciences.org/articles/19432 |
Similar Items
-
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
by: Andrew R Conery, et al.
Published: (2016-01-01) -
Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming
by: Ebrahimi, A, et al.
Published: (2019) -
Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation
by: Denise E. de Almeida Nagata, et al.
Published: (2019-04-01) -
Development of selective CBP/P300 benzoxazepine bromodomain inhibitors
by: Popp, T, et al.
Published: (2016) -
CBP/p300 bromodomain: new promising epigenetic target
by: Xiang Qiuping, et al.
Published: (2022-01-01)